Printer Friendly

GLAXO TO REORGANIZE SEVERAL BUSINESS FUNCTIONS

 GLAXO TO REORGANIZE SEVERAL BUSINESS FUNCTIONS
 RESEARCH TRIANGLE PARK, N.C., Dec. 19 /PRNewswire/ -- In an effort


to maintain the focus and energy that has contributed to Glaxo Inc.'s rapid growth over the last decade, the pharmaceutical company announced today that it is reorganizing several of its business functions into strategic business units.
 The strategic business units, or SBUs, will be known as the Glaxo Pharmaceutical Unit, the Allen & Hanburys Unit, and the Glaxo Technical Operations Unit. The changes take effect Jan. 1, 1992.
 The Glaxo Pharmaceuticals Unit will be headed by Robert A. Ingram, group vice president. It will consist of the Glaxo Pharmaceuticals Sales and Marketing Division led by vice president and general manager Robert H. Zeiger; the Corporate Sales Division led by vice president and general manager James R. Butler; and a new sales and marketing division focusing on medicines for central nervous system disorders, whose vice president and general manager will be named later. Ingram will retain responsibility for federal government affairs and regulatory affairs.
 The Allen and Hanburys Unit will be headed by Thomas W. D'Alonzo, group vice president. It will consist of the Allen & Hanburys Sales and Marketing Division, led by vice president and general manager F. Ronald Stanton, and the Glaxo Dermatology Sales and Marketing Division, led by vice president and general manager Richard A. Franco. D'Alonzo will retain responsibility for the licensing and business development functions.
 The Glaxo Technical Operations Unit will be headed by Clifford H. Disbrow, senior vice president of technical operations, and consist of the manufacturing and packaging, materials management, engineering, and quality assurance functions.
 Each SBU will draw personnel as needed from various areas -- including medical operations, human resources, management information services, legal and strategic planning -- to form separate but closely cooperating organizations within the company. The management of each organization will have sales and profit responsibility, as well as responsibility for all other business functions, within the SBU.
 Ingram, D'Alonzo and Disbrow will report to Charles A. Sanders, Glaxo Inc's chief executive officer. The corporate finance and research and development divisions are unaffected by these changes.
 In other words, Santo J. Costa, previously senior vice president, general counsel and secretary, has assumed additional responsibilities and will become senior vice president, administration and general counsel. Gary S. Freedman, previously vice president and deputy general counsel, has been named vice president, deputy general counsel and secretary.
 In addition, Thomas F. Cecich has been named vice president, safety and environmental affairs. Cecich previously was director of that department.
 -0- 12/19/91
 /CONTACT: Rick Sluder, Corporate Communications, Glaxo Inc., 919-248-2839/ CO: Glaxo Inc. ST: North Carolina IN: MTC SU:


DF -- CH008 -- 4037 12/19/91 15:33 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 19, 1991
Words:449
Previous Article:PNC BOARD APPROVES CCNB ACQUISITION
Next Article:LTV GETS $131.8 MILLION IN CONTRACTS FOR ARMY ROCKET SYSTEM PRODUCTION
Topics:


Related Articles
GLAXO ANNOUNCES ORGANIZATIONAL REALIGNMENT
GLAXO INC. RECEIVES CLEARANCE TO MARKET IMITREX INJECTION
GLAXO INC. RECEIVES ONE OF NORTH CAROLINA'S TOP ENVIRONMENTAL AWARDS FOR ACHIEVEMENT IN WASTE MANAGEMENT
GLAXO ENTERS GENE THERAPY WITH MEGABIOS
NEW DIRECTOR APPOINTED TO HEAD GLAXO RESEARCH INSTITUTE
ACQUISITION COMPLETE, GLAXO INC. AND BURROUGHS WELLCOME LOOK TO FUTURE
PowderJect & Glaxo Wellcome Sign DNA Vaccine Agreement
Ribozyme Pharmaceuticals, Inc. and Glaxo Wellcome Sign Genomics Evaluation Agreement
Senior Executive Appointments Announced for Glaxo SmithKline.
Deltagen Enters Into Gene Function Database and Target Validation Agreements with Glaxo Wellcome.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters